본문 바로가기
KERD
논문KCI 등재

The role of different viral biomarkers on the management of chronic hepatitis B

Rex Wan-Hin Hui|James Fung|Wai Kay Seto|Man-Fung Yuen|Lung-Yi Mak
대한간학회 (The korean Association for the Study of the Liver)|2023.04|Clinical and Molecular Hepatology|제29권 제2호|pp. 263-276

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

Treatment outcomeChronic hepatitis BHepatitis B core antigenViremia

초록

Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess viral activity. In this review article, we summarize the relevant data of how antiviral therapies impact viral biomarkers, and discuss their potential implications. Viral nucleic acids including hepatitis B virus (HBV) double-stranded deoxy-ribonucleic acid (DNA) and to a lesser extent, pre-genomic RNA, are readily suppressed by nucleos(t)ide analogues (NUCs). The primary role of these markers include risk prediction for hepatocellular carcinoma (HCC) and risk stratification for partial cure, defined as off-therapy virological control, or functional cure, defined as hepatitis B surface antigen (HBsAg) seroclearance plus undetectable serum HBV DNA for ≥6 months. Viral translational products including hepatitis e antigen, quantitative HBsAg and hepatitis B core-related antigen can be reduced by NUCs and pegylated interferon a. They are important in defining disease phase, delineating treatment endpoints, and predicting clinical outcomes including HCC risk and partial/ functional cure. As the primary outcome of phase III trials in chronic hepatitis B is set as HBsAg seroclearance, appropriate viral biomarkers can potentially inform the efficacy of novel compounds. Early viral biomarker response can help with prioritization of subjects into clinical trials. However, standardization and validation studies would be crucial before viral biomarkers can be broadly implemented in clinical use.

Abstract

Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess viral activity. In this review article, we summarize the relevant data of how antiviral therapies impact viral biomarkers, and discuss their potential implications. Viral nucleic acids including hepatitis B virus (HBV) double-stranded deoxy-ribonucleic acid (DNA) and to a lesser extent, pre-genomic RNA, are readily suppressed by nucleos(t)ide analogues (NUCs). The primary role of these markers include risk prediction for hepatocellular carcinoma (HCC) and risk stratification for partial cure, defined as off-therapy virological control, or functional cure, defined as hepatitis B surface antigen (HBsAg) seroclearance plus undetectable serum HBV DNA for ≥6 months. Viral translational products including hepatitis e antigen, quantitative HBsAg and hepatitis B core-related antigen can be reduced by NUCs and pegylated interferon a. They are important in defining disease phase, delineating treatment endpoints, and predicting clinical outcomes including HCC risk and partial/ functional cure. As the primary outcome of phase III trials in chronic hepatitis B is set as HBsAg seroclearance, appropriate viral biomarkers can potentially inform the efficacy of novel compounds. Early viral biomarker response can help with prioritization of subjects into clinical trials. However, standardization and validation studies would be crucial before viral biomarkers can be broadly implemented in clinical use.

참고문헌 (106)

  1. Polaris Observatory Collaborators, "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016 : a modelling study", Lancet Gastroenterol Hepatol, 3, pp.383~403 (2018)
  2. Global Hepatitis Report 2017, , World Health Organization, ~ (2017)
  3. Razavi-Shearer D, "The incidence of chronic HBV by age at the global and regional level, 2022", Hepatology, 76, pp.S29~ (2022), Wiley
  4. Ni Y, "Hepatitis B and D viruses exploit sodium taurocholate cotransporting polypeptide for species-specific entry into hepatocytes", Gastroenterology, 146, pp.1070~1083 (2014)
  5. Rabe B, "Nuclear import of hepatitis B virus capsids and release of the viral genome", Proc Natl Acad Sci U S A, 100, pp.9849~9854 (2003)
  6. Wei L, "Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation", Nat Microbiol, 5, pp.715~726 (2020)
  7. Königer C, "Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses", Proc Natl Acad Sci U S A, 111, pp.E4244~E4253 (2014)
  8. Seeger C, "Molecular biology of hepatitis B virus infection", Virology, 479-480, pp.672~686 (2015)
  9. Tuttleman JS, "Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells", Cell, 47, pp.451~460 (1986)
  10. Ko C, "Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels", J Hepatol, 69, pp.1231~1241 (2018)
  11. Tu T, "HBV DNA integration : molecular mechanisms and clinical implications", Viruses, 9, pp.75~ (2017)
  12. Jeong Won Jang, "Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance", Clinical and Molecular Hepatology, 27(1), pp.207~218 (2021), 대한간학회[DOI]
  13. Schmid J, "Placebo analgesia in patients with functional and organic abdominal pain : a fMRI study in IBS, UC and healthy volunteers", Gut, 64, pp.418~427 (2015)
  14. Berg T, "Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study", J Hepatol, 67, pp.918~924 (2017)
  15. Bonvin M, "Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication", Hepatology, 43, pp.1364~1374 (2006)
  16. Lucifora J, "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA", Science, 343, pp.1221~1228 (2014)
  17. Belloni L, "IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome", J Clin Invest, 122, pp.529~537 (2012)
  18. Cornberg M, "Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference", Hepatology (2019)[DOI]
  19. Neuberger J, "Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology", Gut, 69, pp.1382~1403 (2020)
  20. Mani H, "Liver biopsy findings in chronic hepatitis B", Hepatology, 49(5 Suppl), pp.S61~S71 (2009)
  21. Zhao XL, "Serum viral duplex-linear DNA proportion increases with the progression of liver disease in patients infected with HBV", Gut, 65, pp.502~511 (2016)
  22. Wong DK, "Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients", Hepatology, 40, pp.727~737 (2004)
  23. Lin LY, "Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAgnegative patients", J Med Virol, 82, pp.1494~1500 (2010)
  24. Guner R, "Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection", Eur J Gastroenterol Hepatol, 23, pp.1185~1191 (2011)
  25. Gao Y, "Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?", J Clin Microbiol, 55, pp.2972~2982 (2017)
  26. European Association for the Study of the Liver, "EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
  27. Wang J, "Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound", J Hepatol, 65, pp.700~710 (2016)
  28. Giersch K, "Serum HBV pgRNA as a clinical marker for cccDNA activity", J Hepatol, 66, pp.460~462 (2017)
  29. Wang Y, "Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients", Int J Med Sci, 19, pp.858~866 (2022)
  30. Wang J, "Natural history of serum HBV-RNA in chronic HBV infection", J Viral Hepat, 25, pp.1038~1047 (2018)
  31. van Bömmel F, "Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors", Hepatology, 61, pp.66~76 (2015)
  32. Butler EK, "Hepatitis B virus serum DNA and RNA levels in Nucleos(t)ide analog-treated or untreated patients during chronic and acute infection", Hepatology, 68, pp.2106~2117 (2018)
  33. Mak LY, "HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy", Hepatology, 73, pp.2167~2179 (2021)
  34. Wang X, "Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment", Virol J, 18, pp.4~ (2021)
  35. Farag MS, "Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAgnegative chronic hepatitis B", Clin Infect Dis, 72, pp.202~211 (2021)
  36. Ma H, "Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients", J Gastroenterol Hepatol, 25, pp.1498~1506 (2010)
  37. Geng M, "A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs : realworld clinical practice", Int J Infect Dis, 62, pp.18~25 (2017)
  38. Yuen MF, "Hepatitis B virus infection", Nat Rev Dis Primers, 4, pp.18035~ (2018)
  39. Wooddell CI, "RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg", Sci Transl Med, 9, pp.eaan0241~ (2017)
  40. Roche, "Elecsys® HBsAg II: Immunoassay for the qualitative determination of hepatitis B surface antigen (HBsAg)", ~
  41. Maylin S, "Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus", Clin Vaccine Immunol, 19, pp.242~248 (2012)
  42. Wursthorn K, "Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen(HBsAg)in the serum", J Clin Virol, 50, pp.292~296 (2011)
  43. Lou S, "An ultra-sensitive Abbott ARCHITECT® assay for the detection of hepatitis B virus surface antigen(HBsAg)", J Clin Virol, 105, pp.18~25 (2018)
  44. Matsumoto A, "Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody", J Gastroenterol, 52, pp.376~384 (2017)
  45. Shinkai N, "Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance", J Clin Microbiol, 51, pp.3484~3491 (2013)
  46. Wong DK, "Detection of the hepatitis B surface antigen in patients with occult hepatitis B by use of an assay with enhanced sensitivity", J Clin Microbiol, 60, pp.e0220421~ (2022)
  47. Thompson AJ, "Serum hepatitis B surface antigen and hepatitis B e antigen titers : disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers", Hepatology, 51, pp.1933~1944 (2010)
  48. Chan HL, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAgpositive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.185~195 (2016)
  49. Hara T, "Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)idenaïve chronic hepatitis B patients", J Viral Hepat, 21, pp.802~808 (2014)
  50. Ko KL, "A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance", J Viral Hepat, 27, pp.397~406 (2020)
  51. Lam YF, "Seven-year treatment outcome of entecavir in a real-world cohort : effects on clinical parameters, HBsAg and HBcrAg levels", Clin Transl Gastroenterol, 8, pp.e125~ (2017)
  52. Buti M, "Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection", Dig Dis Sci, 60, pp.1457~1464 (2015)
  53. Buti M, "Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection:a randomised, double-blind, phase 3, non-inferiority trial", Lancet Gastroenterol Hepatol, 1, pp.196~206 (2016)
  54. Wong VW, "Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.1945~1953 (2010)
  55. Singh AK, "Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment", J Viral Hepat, 21, pp.439~446 (2014)
  56. Brunetto MR, "Hepatitis B virus surface antigen levels : a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B", Hepatology, 49, pp.1141~1150 (2009)
  57. Mak LY, "Review article : hepatitis B core-related antigen(HBcrAg) : an emerging marker for chronic hepatitis B virus infection", Aliment Pharmacol Ther, 47, pp.43~54 (2018)
  58. Kimura T, "Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load", J Clin Microbiol, 40, pp.439~445 (2002)
  59. Beudeker BJ, "Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B", Antivir Ther, 25, pp.217~222 (2020)
  60. Chuaypen N, "Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B", Liver Int, 36, pp.827~836 (2016)
  61. Inoue T, "Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation", J Hepatol, 75, pp.302~310 (2021)
  62. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
  63. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
  64. Lee HA, "Hepatitis B corerelated antigen is useful for predicting phase and prognosis of hepatitis B e antigen-positive patients", J Clin Med, 11, pp.1729~ (2022)
  65. Ungtrakul T, "Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients", Medicine(Baltimore), 96, pp.e6554~ (2017)
  66. Chan HL, "Hepatitis B surface antigen quantification : why and how to use it in 2011-a core group report", J Hepatol, 55, pp.1121~1131 (2011)
  67. Martinot-Peignoux M, "The role of HBsAg quantification for monitoring natural history and treatment outcome", Liver Int, 33(Suppl 1), pp.125~132 (2013)
  68. Tseng TC, "Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B : new trick of old dog", J Gastroenterol, 48, pp.13~21 (2013)
  69. "Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy", World Health Organization, ~ (2020)
  70. Boucheron P, "Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates : a systematic review and meta-analysis", Lancet Infect Dis, 21, pp.85~96 (2021)
  71. Sun KX, "A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women", Vaccine, 30, pp.5335~5340 (2012)
  72. Wen WH, "Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection", Hepatology, 64, pp.1451~1461 (2016)
  73. Jackson K, "Real-world application of the Xpert® HBV viral load assay on serum and dried blood spots", J Med Virol, 93, pp.3707~3713 (2021)
  74. Abravanel F, "Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA", Diagn Microbiol Infect Dis, 96, pp.114946~ (2020)
  75. Shimakawa Y, "Rapid pointof-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings", Clin Gastroenterol Hepatol (2022)[DOI]
  76. Tseng TC, "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load", Gastroenterology, 142, pp.1140~1149 (2012)
  77. Yuen MF, "HBsAg Seroclearance in chronic hepatitis B in Asian patients : replicative level and risk of hepatocellular carcinoma", Gastroenterology, 135, pp.1192~1199 (2008)
  78. Yip TC, "Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance", J Hepatol, 67, pp.902~908 (2017)
  79. Chen CJ, "Hepatitis B virus DNA levels and outcomes in chronic hepatitis B", Hepatology, 49(5 Suppl), pp.S72~S84 (2009)
  80. Su TH, "Improving clinical outcomes of chronic hepatitis B virus infection", Expert Rev Gastroenterol Hepatol, 9, pp.141~154 (2015)
  81. Jer-Wei Wu, "Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(4), pp.524~534 (2021), 대한간학회[DOI]
  82. Takako Inoue, "Novel biomarkers for the management of chronic hepatitis B", Clinical and Molecular Hepatology, 26(3), pp.261~279 (2020), 대한간학회[DOI]
  83. Lung-Yi Mak, "Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma", Gut and Liver, 14(5), pp.665~668 (2020), 거트앤리버 소화기연관학회협의회[DOI]
  84. Cheung KS, "Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy", J Viral Hepat, 24, pp.654~661 (2017)
  85. Mak LY, "Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy", J Gastroenterol, 56, pp.479~488 (2021)
  86. Liem KS, "Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B : results from a randomised controlled trial(Toronto STOP study)", Gut, 68, pp.2206~2213 (2019)
  87. Chen CH, "Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection", Clin Gastroenterol Hepatol, 13, pp.1984~1992 (2015)
  88. Chen CH, "Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients", Clin Microbiol Infect, 24, pp.997~1003 (2018)
  89. Jeng WJ, "Clinical relapse after cessation of tenofovir therapy in hepatitis B e antigen-negative patients", Clin Gastroenterol Hepatol, 14, pp.1813~1820 (2016)
  90. Sonneveld MJ, "Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)", Clin Gastroenterol Hepatol, 20, pp.e784~e793 (2022)
  91. Seto WK, "Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation", Gut, 70, pp.775~783 (2021)
  92. Fan R, "Combining hepatitis B virus RNA and hepatitis B core-related antigen: guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis", J Infect Dis, 222, pp.611~618 (2020)
  93. Papatheodoridi M, "Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy", J Viral Hepat, 29, pp.948~957 (2022)
  94. Hirode G, "Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B:an international, multicenter, multiethnic cohort (RETRACT-B Study).", Gastroenterology, 162, pp.757~771 (2022)
  95. Berg T, "The times they are a-changing-A refined proposal for finite HBV nucleos(t)ide analogue therapy", J Hepatol, 75, pp.474~480 (2021)
  96. Lung-Yi Mak, "Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B", Clinical and Molecular Hepatology, 29(1), pp.146~162 (2023), 대한간학회
  97. Sun Woong Kim, "Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus", Clinical and Molecular Hepatology, 28(1), pp.17~30 (2022), 대한간학회[DOI]
  98. Mak LY, "New strategies for the treatment of chronic hepatitis B", Trends Mol Med, 28, pp.742~757 (2022)
  99. Yuen MF, "Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB", J Hepatol, 77, pp.1287~1298 (2022)
  100. Yuen MF, "Efficacy and safety of bepirovirsen in chronic hepatitis B infection", N Engl J Med, 387, pp.1957~1968 (2022)
  101. Young-Suk Lim, "New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?", Clinical and Molecular Hepatology, 29(1), pp.118~119 (2023), 대한간학회
  102. Sulkowski MS, "Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection", J Hepatol, 77, pp.1265~1275 (2022)
  103. Agarwal K, "Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor : A randomized, placebocontrolled phase 1 study", J Viral Hepat, 30, pp.209~222 (2023)
  104. Zoulim F, "JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1study of patients with chronic infection", Gastroenterology, 159, pp.521~533 (2020)
  105. Yuen MF, "Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection", Gastroenterology, 156, pp.1392~1403 (2019)
  106. Hou J, "Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with", without Peg-IFN in chronic hepatitis B patients, 2022, pp.77, S299~

관련 논문AI추천

New Biomarkers of Chronic Hepatitis BJames Fung, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제6호Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis BAaron Hamilton, Alison Kuchta, Danny Wong, Lung-Yi Mak, Man Fung Yuen, Martina Hilfiker, Ning Chow, Wai Kay Seto, Xianhua Mao대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapyTakako Inoue, Takehisa Watanabe, Yasuhito Tanaka대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제4호Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parametersDanny Ka-Ho Wong, Gavin Cloherty, Lung-Yi Mak, Man-Fung Yuen, Mark Anderson, Matthew Shing-Hin Chung, Michael Stec, Rex Wan-Hin Hui, Wai-Kay Seto대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Novel biomarkers for the management of chronic hepatitis BTakako Inoue, Yasuhito Tanaka대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제3호Global strategies and actions to eliminate hepatitis B virus infectionChih-Lin Lin, Jia-Horng Kao대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제4호

이 간행물의 다른 논문 (53건)

Congratulatory remarksSi Hyun Baepp. 1-1Special thanksSeung Up Kimpp. 4-4MAFLD: How is it different from NAFLD?Ming-Hua Zheng, Jacob George, Cameron Gofton, Yadhavan Upendranpp. 17-31Global incidence and prevalence of nonalcoholic fatty liver diseaseEunice Tan, Mark D. Muthiah, Cheng Han Ng, Margaret LP Teng, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Daniel Q. Huangpp. 32-42Nonalcoholic fatty liver disease and non-liver comorbiditiesRichie Manikat, Mindie H. Nguyenpp. 86-102
원문 보기